Vaccinex, Inc. (VCNX): R&D Expense
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$12.54M
Year ended 2024-12-31
-9.9%
3-year compound annual growth
-13.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $12.54M | -24.3% | 2025-04-15, From 2024-01-01 |
| 2023-12-31 | $16.57M | +18.6% | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | $13.98M | -18.5% | 2024-04-25, From 2022-01-01 |
| 2021-12-31 | $17.16M | -20.4% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $21.55M | -16.1% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $25.67M | +14.8% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $22.35M | +35.1% | 2020-03-09, From 2018-01-01 |
| 2017-12-31 | $16.55M | n/a | 2019-03-13, From 2017-01-01 |